ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BCDAW BioCardia Inc

0.0127
-0.0003 (-2.31%)
06 Jul 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
BioCardia Inc NASDAQ:BCDAW NASDAQ Equity Warrant
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.0003 -2.31% 0.0127 0.0025 0.0175 0.013 0.0127 0.013 5,894 05:00:08

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

26/08/2020 12:00pm

GlobeNewswire Inc.


BioCardia (NASDAQ:BCDAW)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more BioCardia Charts.

BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today announced that Peter Altman, Ph.D., Biocardia’s Chief Executive Officer will give a virtual corporate presentation at the LD Micro 500 taking place online on Tuesday, September 1, 2020 at 10:20 AM ET followed by a live question and answer session with registered investors and other conference attendees.

Webcast link: https://www.webcaster4.com/Webcast/Page/2019/36064

In addition, Dr. Altman will be available for virtual one-on-one meetings beginning on September 1, 2020 and through September 4, 2020.  To schedule a meeting, please contact Eric Lahiji at eric@ldmicro.com.

About BioCardia

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit www.BioCardia.com.

Media Contact:Michelle McAdam, Chronic Communications, Inc.michelle@chronic-comm.com(310) 902-1274

Investor Contact:David McClung, Chief Financial OfficerInvestors@BioCardia.com(650) 226-0120

1 Year BioCardia Chart

1 Year BioCardia Chart

1 Month BioCardia Chart

1 Month BioCardia Chart

Your Recent History

Delayed Upgrade Clock